SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

$CAW.X is trending due to its recent listing on Coinbase, sparking excitement within the community. Discussions highlight its multichain functionality across $SOL.X, BSC, $CRO.X, and $ETH.X (BASE) and deflationary mechanisms, as well as the potential for significant gains.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss recent disclosures of a Senator taking a large position in the stock, along with Goldman Sachs increasing their holdings, fueling speculation of significant upcoming government contracts. The community is buzzing with excitement, drawing comparisons to Palantir and anticipating a potential short squeeze. Many are highlighting the company's connections to the TSA and potential for further government contracts, contributing to the positive sentiment.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors weigh its potential amid the EV sector's challenges, with community discussions focusing on technical analysis suggesting a possible breakout. A mix of opinions highlights both bullish sentiment around future growth and skepticism related to cash burn and competition. Recent news, such as the groundbreaking of their Georgia plant, has further fueled community discussion.

MicroCloud Hologram, Inc. engages in research, development, and application of holographic technology. It operates through the Holographic Solutions and Holographic Technology Service segments. The company was founded in 2020 and is headquartered in New York, NY.

MicroCloud Hologram Inc

MicroCloud Hologram is trending as investors discuss potential catalysts, including its cryptocurrency holdings and anticipation of a partnership announcement. Bullish traders are pointing to technical indicators, while others debate the company's financials and compare it to related tickers. The community hopes for a significant price surge, referencing past rallies and potential news catalysts.

Shineco, Inc. is a holding company, which through its subsidiaries, engages in the production and distribution of plant-based products. It operates through the following segments: Rapid Diagnostic and Other, Other Agricultural, and Healthy Meals Products. The Rapid Diagnostic and Other Products segment is conducted through Biowin, which specializes in the development, production and distribution of innovative rapid diagnostic products and related medical devices for the most common diseases. The Other Agricultural Products segment is conducted through Wintus, which specializes in producing, processing and distribution of agricultural products, such as silk and silk fabrics as well as trading of fresh fruit. The Healthy Meals Products segment is conducted through Fuzhou Meida, which specializes in developing healthy meals for people with slow metabolic health and those in recovery from metabolic disorders. The company was founded on August 20, 1997 and is headquartered in Beijing, China.

Shineco Inc

SISI is trending due to a recent announcement regarding the launch of an on-chain cell asset tokenization platform, sparking community interest in its potential within the bioeconomy and blockchain space. The community is actively discussing the company's small float and potential for a short squeeze, drawing comparisons to other low-float runners. Some caution against the stock due to it being a China-based company.

The vision behind $DAIO's Reward System is simple. Those that hold and buy dips should be rewarded over jeets or buy pressure sellers. In theory if everyone held together the coin would go up right?  Sadly that is not the case but the DAIO feels those that are loyal to a coin shall be rewarded. First use case is $DAIO and the agents that follow. Phase II will unlock it's second use case, the Solana blockchain.

Decentralized AI Organization

Decentralized AI Organization ($DAIO.X) is trending as community members express excitement about its potential, with many mentioning 'pump' and encouraging others to buy in early. Some users are highlighting its availability on Phantom wallet and drawing comparisons to other AI-related crypto projects. The focus remains on community building and upward momentum.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Fueled by news of a significant energy storage contract in Spain, Turbo Energy S.A. - ADR ($TURB) is experiencing a surge in trading volume and price. Community members are actively discussing potential price targets, short squeezes, and comparisons to other high-flying stocks with similar low floats, while also debating the sustainability of the current momentum and identifying potential copycat plays for tomorrow.

"Shina Inu is a decentralized meme token on the Ethereum blockchain. Its mission is to give back to the crypto community, give to charity, and win the heart of the greatest token of all time, Shiba Inu!   Shina Token is a very fun meme token project that has sold many rare and beautiful NFTs. NFT sales are used to support the team and provide upcoming features such as exclusive access to events and rewards that will soon be announced."

Shina Inu

Shina Inu is trending as community members highlight positive sentiment and technical indicators, suggesting a potential breakout is on the horizon. Chatter suggests a controlled uptrend and accumulation phase, with buyers showing patience and strength. Some community members are comparing it to Shiba Inu and anticipating a significant move.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to a significant intraday surge, reportedly fueled by speculative momentum and a potential short squeeze within the small-cap sector. Community discussions highlight the stock's massive run and are comparing it to other low float movers, while some caution against chasing the rally. The company's growth potential and gross margin expectations are also being noted.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members highlight its strong, decentralized community and fair distribution, setting it apart from other meme coins. There's excitement around potential exchange listings and its connection to Bitcoin's ecosystem. Some community members also highlight a partnership between Dog of Bitcoin Foundation and C2 Blockchain Inc.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results in multiple cohorts of its Phase 1b/2a BEACON study evaluating briquilimab for chronic spontaneous urticaria (CSU), a skin allergy.BMO Capital cut the stock to 'Market Perform' from 'Outperform' and slashed its price target to $4 from $15, citing uncertainty caused by manufacturing issues that made it “challenging to separate the signal from the noise.”Cantor Fitzgerald also downgraded the shares to 'Neutral' from 'Overweight', saying the update “introduced uncertainty for clinical trial execution and development timelines.”&nbsp;The firm said it would wait for clarity on future Phase 2b regimens and timelines before re-engaging.William Blair issued a similar downgrade to 'Market Perform' from 'Outperform', flagging a lack of clarity around funding and concerns over the inactive drug lot, which also led Jasper to halt briquilimab development in asthma.&nbsp;The company confirmed that the affected batch was used in all patients in its ETESIAN asthma study.BTIG reduced its price target to $20 from $64 but maintained a 'Buy' rating, calling briquilimab “safe and active” with “compelling efficacy,” despite the paused asthma trial and delayed Phase 2b CSU start, now expected mid-2026.H.C. Wainwright dropped its target to $20 from $40 and retained a 'Buy' rating, citing the “surprising update” on the affected cohorts.&nbsp;The research firm shifted U.S. launch estimates for CSU and chronic inducible urticaria to 2030 and 2031, respectively, and now models a $5 million capital raise.Jasper said the affected cohorts — 240 mg Q8W and 240 mg loading dose plus 180 mg Q8W — showed little to no clinical response, with 10 of 13 patients dosed from the compromised batch.&nbsp;The company plans to replace the products for those patients and enroll 10–12 more across both cohorts. New data is expected in the fourth quarter.Across other cohorts, briquilimab produced deep and durable disease control.&nbsp;In the 240 mg and 360 mg single-dose groups, 8 of 9 participants achieved a complete response, with strong reductions in UAS7 and tryptase levels.&nbsp;Results from the open-label extension study also showed promising efficacy.Jasper is halting asthma and SCID development and may restructure to cut costs and extend its runway.However, retail sentiment for&nbsp;<a href="https://stocktwits.com/symbol/JSPR">Jasper Therapeutics</a> on Stocktwits was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said Jasper looked oversold and predicted a move above $5, calling the reaction to the update an overreaction to 90% good news.<stembedurl>https://stocktwits.com/trt102967/message/620133879</stembedurl>Another user compared the situation to&nbsp;<a href="https://stocktwits.com/symbol/CAPR/news">Capricor Therapeutics</a> , which dropped last month after reports that&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-slumps-on-report-of-key-fda-exec-removal/chlxVk2RRPt">two key FDA officials</a> overseeing the company’s cell therapy application were placed on administrative leave.<stembedurl>https://stocktwits.com/jlove0303/message/620128019</stembedurl>Jasper Therapeutics’ stock has declined 85.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Jasper Therapeutics (JSPR) is investigating a compromised drug batch in its briquilimab skin allergy trial/ Photo credit: Getty Images

Jasper Therapeutics Gets Hit With Downgrades Over Faulty Batch Of Skin Allergy Drug; Retail Sees ‘Overreaction’

The company flagged that 10 of 13 patients in two dosing cohorts received a compromised batch of briquilimab, leading to muted results.

Equity

Futures Slump As Yields, Dollar Soar

Futures Slump As Yields, Dollar Soar

 US equity futures were already rolling over following yesterday's momentum-driven rout, when a the latest report out of CNN (a polar opposite to the...

Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday?

Jasper Therapeutics' SPOTLIGHT study reports 93% clinical response in cold urticaria and symptomatic dermographism. The 120mg dose showed 83% complete response and no severe adverse events. Full data...

Optimistic Buy Rating for Jasper Therapeutics as Briquilimab Shows Promising Trial Progress

TD Cowen analyst Yaron Werber has maintained their bullish stance on JSPR stock, giving a Buy rating today. Yaron Werber has given his Buy rating d...

Buy Rating for Jasper Therapeutics: Clinical Progress and Financial Stability Signal Strong Potential

Analyst Tim Chiang of Capital One Financial assigned a Buy rating on Jasper Therapeutics (JSPR Research Report), retaining the price target of $5...

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Jasper Therapeutics (JSPR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD Research Report) and Jasper Therapeutics...

TD Cowen Remains a Buy on Jasper Therapeutics (JSPR)

TD Cowen analyst Yaron Werber maintained a Buy rating on Jasper Therapeutics (JSPR Research Report) today. The company's shares closed yesterday...

Buy Rating for Jasper Therapeutics: Promising Pipeline and Market Disruption Potential with Briquilimab

Jasper Therapeutics (JSPR) has received a new Buy rating, initiated by BTIG analyst, Justin Zelin. Justin Zelin has given his Buy rating due to a c...

Jasper Therapeutics initiated with bullish view at Evercore ISI, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy...

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.

Jasper Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

JSPR
Jasper Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JSPR News

JSPR Jasper Therapeutics Inc